US equities |
MU $1,070.43 ▲+0.50% NVDA $230.44 ▲+0.90% SNDK $1,776.88 ▲+2.13% GOOGL $337.85 ▼-1.81% TSLA $355.94 ▲+0.32% INTC $120.42 ▲+0.16% SPCX $149.90 ▼-0.64% AAPL $328.28 ▼-1.42%
FinancialContent Watchlist

Schrodinger, Inc. - Common Stock (NQ:SDGR)

30.59 -0.46 (-1.50%)
Delayed Quote Updated: 1:17 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Schrodinger, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Schrödinger to Announce First Quarter 2022 Financial Results on May 4
From Schrödinger
Via Business Wire
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
News headline image
AI Pharma Startup METiS Raises $150 Million. IPO In Sight? ↗
Key takeaways: METiS Pharmaceuticals has completed five funding rounds since its establishment in January 2020, including the latest two worth $150 million The company was... 
Via Benzinga
News headline image
Schrödinger New Preclinical Data Supports Development Of Its Wee1 Inhibitor In Cancer Indications ↗
Schrödinger Inc (NASDAQ: SDGR)  
Via Benzinga
News headline image
Schrodinger: Q4 Earnings Insights ↗
Schrodinger (NASDAQ:SDGR) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
Preview: Schrodinger's Earnings ↗
Schrodinger (NASDAQ:SDGR) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Why Jim Cramer Recommends Selling AGNC Investment ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Schrodinger Inc (NYSE: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Schrödinger Reports New Preclinical Data Supporting Advancement of Its Wee1 Inhibitor Program at American Association of Cancer Research 2022 Annual Meeting
From Schrödinger, Inc.
Via Business Wire
News headline image
3 Hypergrowth Tech Stocks to Buy for Huge Upside Potential ↗
These hypergrowth stocks are bargains after retreating for much of the last year. They will all perform very well for long-term investors. 
Via InvestorPlace
News headline image
Expert Ratings For Schrodinger ↗
Over the past 3 months, 5 analysts have published their opinion on Schrodinger (NASDAQ: 
Via Benzinga
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
Via Benzinga
News headline image
93 Biggest Movers From Friday ↗
Gainers Inspirato Incorporated (NASDAQ: ISPO) shares surged 50.5% to close at $54.90. Guardforce AI Co., Limited (NASDAQ: GFAI) jumped 45.4% to settle at $0.5979 on Friday. EF... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Aerie Pharmaceuticals (NASDAQ:AERI) shares increased by 28.1% to $7.56 during Friday's regular session. Trading volume for Aerie Pharmaceuticals's stock is... 
Via Benzinga
News headline image
45 Stocks Moving In Friday's Mid-Day Session ↗
Gainers KAR Auction Services, Inc. (NYSE: KAR) shares climbed 39.2% to $19.05 after the company agreed to sell its ADESA U.S. physical auction business to Carvana for $2.2... 
Via Benzinga
News headline image
Schrödinger Reports Financial Results for the Fourth Quarter and Full Year 2021
From Schrödinger, Inc.
Via Business Wire
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
News headline image
3 Desirable Drug Stocks With Very Promising Pipelines ↗
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider. 
Via InvestorPlace
News headline image
Schrödinger to Announce Fourth Quarter and Full-Year 2021 Financial Results on February 24
From Schrödinger
Via Business Wire
News headline image
Schrödinger to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference
From Schrödinger
Via Business Wire
News headline image
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
News headline image
Schrödinger Announces Acquisition of XTAL BioStructures, Inc.
From Schrödinger, Inc.
Via Business Wire
News headline image
Schrödinger to Present at H.C. Wainwright BioConnect Conference
From Schrödinger, Inc.
Via Business Wire
News headline image
Schrödinger Announces Retirement of Chief Financial Officer Joel Lebowitz
From Schrödinger, Inc.
Via Business Wire
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
News headline image
3 Stocks That Can Make You Rich in Just a Few Years ↗
Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed. 
Via InvestorPlace
News headline image
Schrödinger Reports Preclinical Data Supporting Advancement Of Its MALT1 Inhibitor Program At American Society Of Hematology 2021 Annual Meeting
From Schrödinger
Via Business Wire
News headline image
Schrödinger to Participate in Five Upcoming Investor Conferences
From Schrödinger
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >